Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

HHS Secretary Sebelius Announces Senate Confirmation Of Assistant Secretary For Preparedness And Response Dr. Nicole Lurie
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius announced today that the United States Senate unanimously confirmed Dr. Nicole Lurie as the next Assistant Secretary for Preparedness and Response at HHS. Dr. Lurie, an internationally recognized leader in public health, most recently served as co-director of the RAND Corporation Center for Domestic and International Health Security, senior natural scientist and professor of policy analysis at the RAND Corporation.
generic viagra online
Flu Virus Ill-Suited For Rapid Transmission, But Researchers Say New Strain Bears Watching, Could Mutate
A team from MIT and the Centers for Disease Control and Prevention has found a genetic explanation for why the new H1N1 "swine flu" virus has spread from person to person less effectively than other flu viruses.
plastic surgery before after
News of the day
Brits Abroad Leave Depressed Friends At Home
New research reveals Brits prefer to rearrange or cancel their summer holiday than go with a friend who has mental illness. The British would prefer to go on their summer holiday with a friend who has a criminal record than go with a friend who has a mental health problem, a new survey as part of the Time to Change campaign [1] has found.
Mental Health

InDex Pharmaceuticals AB Engages PharmaVentures To Facilitate The Licensing Of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early

PharmaVentures Ltd, announced that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures" transactions experience in the healthcare and investment business sectors. Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials. Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program. Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors." A leading results driven organisation, PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company"s core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports. InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis. PharmaVentures


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009